Suicide Gene Therapy

Gene therapy is an emerging line of treatment for mesothelioma and lung cancer, as well as other types of cancer. This promising treatment technique allows doctors to insert a gene directly into a patient’s cells instead of using drugs or surgery. Sometimes gene therapy is used to boost the patient’s immune system. In other cases, the treatment is used to alter the genes in cancer cells, making them more susceptible to treatment.

Mesothelioma and asbestos-related lung cancer are notoriously aggressive and difficult to treat. For these devastating diseases, suicide gene therapy is particularly promising. Researchers are working through clinical trials using gene modification to force cancer cells to self-destruct after being targeted with certain drugs. These promising clinical trials could potentially lead to readily available treatment for most patients.

What is Gene Therapy?

Gene therapy is any treatment that manipulates genetic material. A gene is a sequence of nucleotides in DNA that provides a code for how a cell functions. Cancer cells have genes that prevent them from dying. This is why cancer cells grow and spread uncontrollably, causing disease.

Most types of gene therapy involve inserting a desired gene into a cell’s DNA. This is done through the use of a viral vector. A virus is inactivated so that it will not cause illness, and then its DNA is manipulated to include a gene to be inserted into the DNA of a cancer or healthy cell. The virus is then injected into the patient, targets the correct cell, and inserts the gene. The result may be that the patient’s immune cells begin attacking cancer cells. In the case of suicide gene therapy, cancer cells activate drugs that cause them to self-destruct.

What is Suicide Gene Therapy?

Suicide gene therapy is related to chemotherapy, one of the most effective treatment strategies for mesothelioma. Chemotherapy uses toxic drugs that target cells that divide and grow rapidly. In most cases, the drugs are administered intravenously and circulate through the bloodstream. These drugs are nonspecific, affecting both cancerous and healthy cells. As a result, healthy cells are commonly damaged, causing terrible side effects.

Suicide gene therapy specifically targets cancer cells with these toxic drugs, avoiding damage to healthy cells. Targeted chemotherapy has been a major challenge in cancer treatment. Suicide gene therapy starts with a genetically-modified virus, most often the herpes simplex virus. The virus is first adapted so that it will not infect the patient with herpes. Then, a gene that codes for a special protein is inserted into the virus’s genetic material.

The patient is then injected with the virus and a chemotherapy prodrug. A prodrug is an inactive form of a drug. Because it is inactive, it does not target and kill healthy cells. Like other chemotherapy drugs, it circulates in the body and is drawn into any fast-growing cells. However, because the drug is not activated, it does not harm any healthy cells. The drug that has been studied and used along with the herpes virus to treat cancers is called ganciclovir.

The gene from the virus is inserted into the DNA of the cancer cells. When the prodrug reaches the cancer cells, the gene expresses a special protein and the drug becomes activated. The drug then kills the cancer cells. In other words, the newly inserted gene forces the cancer cells to “commit suicide.” Suicide gene therapy provides a method of targeted activation for chemotherapy drugs to affect cancer cells without affecting healthy cells.

The Bystander Effect

A phenomenon known as the bystander effect helps increase the number of cancer cells that die during suicide gene therapy. The effect occurs when the gene from the herpes virus is inserted to one cell and has an effect on surrounding cells, even if those cells did not successfully receive the gene from the virus. Through means not entirely understood, the toxic drug is transported from one cell to another, causing the cells without the suicide gene to die as well. The bystander effect may play an important role in advancing suicide gene therapy.

Suicide Gene Clinical Trials

This strategy for targeting cancer cells has been used in clinical trials with promising results. Some patients with mesothelioma and lung cancer have benefited from the therapy. Animal studies have also proven the efficacy of this treatment strategy. Although trials are not demonstrating suicide gene therapy is a cure for mesothelioma, it may extend a patient’s life the serious side effects that commonly accompany chemotherapy.

Suicide Gene Therapy Going Forward

Suicide gene therapy presents some challenges. For example, the transfer of genes to the cancer cells is not foolproof and does not work for every patient. In fact, the efficiency of transferring the gene is low and many patients never get the gene inserted into their cancer cells. Although the bystander effect helps, it is not always enough. Other challenges include the possibility of side effects. While most patients experience only mild side effects, liver problems, skin disorders, inflammation, fevers, and anemia are possibilities.

As researchers continue to work on suicide gene therapy for mesothelioma and lung cancer, they must improve the efficiency of gene transfer while minimizing side effects. Researchers may also combine suicide gene therapy with other treatments for greater effectiveness. Combining suicide gene therapy with treatments that boost the patient’s immune system could provide a two-pronged approach to cancer treatment. Combining this therapy with surgery or radiation may also increase effectiveness.

Gene therapy is an exciting area of research, especially for patients living with diseases like mesothelioma. Gene manipulation is becoming easier, safer, and faster safer as technology improves. Suicide gene therapy provides amazing potential for new and effective treatments for all kinds of cancer, including mesothelioma and lung cancer. This emerging therapy provides hope for those living with cancer.

Page Edited by Patient Advocate Dave Foster

Dave has been a mesothelioma Patient Advocate for over 10 years. He consistently attends all major national and international mesothelioma meetings. In doing so, he is able to stay on top of the latest treatments, clinical trials, and research results. He also personally meets with mesothelioma patients and their families and connects them with the best medical specialists and legal representatives available.

Connect with Patient Advocate Dave Foster